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Heart failure (HF) is a complex clinical syndrome characterised by sig-
nificant morbidity and mortality worldwide. Evidence-based thera-
pies for the management of HF include several well-established neu-
rohormonal antagonists and antiarrhythmic drug therapy to miti-
gate the onset of cardiac arrhythmia. However, the degree of rate and
rhythm control achieved is often suboptimal and mortality rates con-
tinue to remain high. Implantable cardioverter-defibrillators (ICDs),
cardiac resynchronization (CRT), and combined (CRT-D) therapies
have emerged as integral and rapidly expanding technologies in the
management of select patients with heart failure with reduced ejec-
tion fraction (HFrEF). ICDs treat ventricular arrhythmia and are used
as primary prophylaxis for sudden cardiac death, while CRT resyn-
chronizes ventricular contraction to improve left ventricular systolic
function. Left ventricular assist device therapy has also been shown
to provide clinically meaningful survival benefits in patients with
advanced HF, and His-bundle pacing has more recently emerged
as a safe, viable, and promising pacing modality for patients with
CRT indication. Catheter ablation is another important and well-
established strategy for managing cardiac arrhythmia in HF, demon-
strating superior efficacy when compared with antiarrhythmic drug
therapy alone. In this article, we provide a comprehensive and in-
depth evaluation of the role of implantable devices and catheter ab-
lation in patients with HFrEF, outlining current applications, recent
advances, and future directions in practice.
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1. Introduction
Heart failure (HF) is a leading cause of morbidity and
mortality worldwide. Cardiac arrhythmias, whether symp-
tomatic or not, are common in all forms of HF. Atrial fibril-
lation (AF) and heart failure with reduced ejection fraction
(HFrEF) are two of the most commonly encountered cardiac
diseases that often co-exist and exacerbate one another [1].
Commonmechanisms that underly the development of AF in
HF include an elevation in left ventricular (LV) filling pres-
sure secondary to systolic and diastolic dysfunction with con-
comitant atrial stretch, increased interstitial fibrosis leading
to abnormal atrial conduction properties, dysregulation of in-
tracellular calcium metabolism and alteration to depolariza-
tion patterns, and neurohormonal dysfunction [2]. AF may
also precipitate the onset of HF by altering the efficiency of
systolic and diastolic timing, leading to a shortened LV filling
time, suboptimal rate control, and reduced myocardial con-
tractility [3]. Ventricular tachyarrhythmias including ven-
tricular tachycardia (VT) or ventricular fibrillation (VF) are
also common in HF. These pathologies result from myocar-
dial hypertrophy and sustainedmechanical stretch, leading to
stretch-induced ventricular arrhythmogenicity, and myocar-
dial fibrosis and scar formation post-myocardial infarction
with the induction of re-entrant VT [4].
Over the last few decades, beta-blockers, angiotensin
receptor–neprilysin inhibitors (ARNis), and mineralocorti-
coid receptor antagonists (MRAs) have continued to demon-
strate favourable reductions in mortality and hospitalization
for HF [5]. Antiarrhythmic drug (AAD) therapy can also be
used to reduce tachyarrhythmia-related symptoms, however
many challenges continue to exist [6]. Catheter ablation has
emerged as a superior alternative to pharmacological man-
agement especially in those who are drug intolerant or for
whomdrug therapy is ineffective [7]. Device therapy has also
become increasingly integral, encompassing a broad range
of technologies for both acute (e.g., the intra-aortic balloon
counterpulsation pump) and non-acute (e.g., left ventricular
assist device) applications [8]. Their predominant indication
however is to prevent sudden cardiac death (SCD) by treat-
ing VT or VF via an implantable cardioverter-defibrillator
(ICD) or to provide cardiac resynchronization (CRT). Multi-
ple clinical trials have since established the survival and qual-
ity of life (QoL) benefits of ICDs, CRTs, and their combina-
tion (CRT-D) in patients with HF [9, 10]. A flowchart illus-
trating treatment selection is presented in Fig. 1. His-bundle
pacing has more recently emerged as a novel, safe, and al-
ternative pacing modality to biventricular pacing in patients
with HF and left bundle branch block (LBBB), and in patients
with narrow QRS and PR prolongation [2, 11]. In light of
recent advances, this review aims to provide a comprehen-
sive and in-depth evaluation of the current role and future
trajectory of implantable devices and catheter ablation in the
contemporary management of HFrEF.
2. Implantable cardioverter defibrillators
2.1 Implantable cardioverter defibrillator versus pharmacological
therapy
ICDs are an important component in the prevention of
SCD in patientswithVT, reducing all-causemortality in both
primary and secondary prevention populations with poor
left ventricular ejection fraction (LVEF) due to ischaemic
or non-ischaemic cardiomyopathy (Table 1, Ref. [12–17]).
The Multicenter Automatic Defibrillator Implantation Trial
II (MADIT)-II study by Moss et al. [13] was the first ran-
domized trial to successfully demonstrate the lifesaving ben-
efits of prophylactic ICD therapy. After randomization of
1232 post-myocardial infarction patients with LVEF ≤30%
to ICD versus medical therapy, the primary outcome of all-
cause mortality was significantly lower in the ICD arm at a
mean follow-up of 20 months (14.2% vs. 19.8%, respectively;
predominantly attributed to a reduction in SCD [18]). How-
ever, hospitalization for HFwas notablymore frequent in pa-
tients with ICD. Unlike MADIT-I, which demonstrated an
early survival benefit with ICD, no mortality reduction was
observed until nine months in MADIT-II [12].
The survival benefit of an implanted ICDwas later shown
to be in concordance with data from the Sudden Cardiac
Death inHeart FailureTrial (SCD-HeFT).Designed to inves-
tigate whether amiodarone or a conservatively programmed
shock-only ICD would reduce the primary outcome of all-
cause mortality among 2521 patients with NYHA class II/III
and LVEF≤35% [15], ICD implantation resulted in a 23% re-
duction in the risk of death from any cause and an absolute 7%
decrease in mortality at a mean follow-up of 45.5 months. As
with MADIT-II, worsening HF was the most common cause
of mortality. This outcome may be attributed to the onset of
inappropriate defibrillator shocks resulting in myocardial in-
jury. Moreover, increased fibrosis may increase defibrillation
thresholds, thus requiring higher energy defibrillations dur-
ing subsequence arrhythmic events (fibrotic areas may also
lead to new arrhythmogenic re-entry circuits) [19]. The in-
duction of VF to test the correct sensing and defibrillation
properties during implantation may also result in myocardial
cell damage, and increased mortality may be due in part to
the adverse psychological effects of an ICD stock, including
anxiety and reactive depression [20]. Although no benefit
was observed with amiodarone, its use will likely continue to
be employed for the suppression of ambient ventricular ar-
rhythmia amongst ICD recipients owing to its minimal pro-
arrhythmic profile [21].
Regarding primary prevention therapy with ICDs in a
non-ischaemic cardiomyopathy patient cohort, Kadish et al.
[14] randomized 458 patients to single-chamber ICD plus
medical therapy versus medical therapy alone in the Defib-
rillators in Non-Ischemic Cardiomyopathy Treatment Eval-
uation (DEFINITE) study, and demonstrated no significant
difference in the primary endpoint of all-cause mortality at
a mean follow-up of 26 months. However, a significant re-
duction in mortality due to arrythmia was reported with ICD
use. These findings were later found to be in concordance
with data from the Danish Study to Assess the Efficacy of
ICDs in Patients withNon-ischemic Systolic Heart Failure on
Mortality (DANISH) [16], whereby randomization of 1116
patients with non-ischaemic cardiomyopathy to ICD versus
usual clinical care demonstrated no statistically significant
difference in all-cause mortality, death from cardiovascular
causes, or safety events at a median follow-up of 68 months
(despite a statistically significant reduction in SCD). Of note,
an age-by-therapy interaction was observed as part of this
study whereby younger patients derived a mortality bene-
fit from ICD therapy whereas older patients (who are more
likely to be at greater risk of complications e.g., lead fracture,
device failure, infection necessitating system extraction, and
death andHF-related hospitalization [22]) did not, highlight-
ing the importance of careful patient selection. Moreover, it
is possible that the relatively high rate of non-cardiovascular
mortality may have led to an underestimation of the effects
of ICD therapy.
In another study, the Prospective Comparison of ARNi
with ACEi (angiotensin converting enzyme inhibitor) to De-
termine Impact on Global Mortality and Morbidity in Heart
Failure Trial (PARADIGM-HF) by McMurray et al. [23]
reported the superiority of the potentially antiarrhythmic
ARNi versus enalapril in reducing the risk of death and hos-
pitalization for HF in 8442 patients with NYHA class II-IV
and LVEF ≤40%. However, it should be noted that a low
percentage of patients within this study were in receipt of an
ICD [24].
2.2 Subcutaneous implantable cardioverter defibrillators
In addition to transvenous ICDs, subcutaneous ICDs (s-
ICDs) were originally designed to mitigate the risk of lead
failure and systemic infection associated with the endovas-
cular leads of transvenous devices [25, 26]. Although S-
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Fig. 1. Flowchart for treatment selection of device therapy or catheter ablation in patients with HF. AAD, antiarrhythmic drug; ACEi, angiotensin
converting enzyme inhibitor; HHF, hospitalization for HF; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association; OMT, optimal medical therapy; SCD, sudden cardiac death.
ICDs are less prevalent than transvenous ICDs, their im-
plantation is increasing [27]. The landmark Prospective
Randomized Comparison of Subcutaneous and Transvenous
Implantable Cardioverter Defibrillator Therapy (PRAETO-
RIAN) study by Knops et al. [17] was the first randomized
trial to compare subcutaneous versus transvenous ICDs. Af-
ter randomization of 849 patients with class I or IIa indica-
tion for single-chamber ICD, device-related complications,
inappropriate shocks, and hospitalization for HF were simi-
lar between groups at amedian follow-up of 49.1months. Al-
though promising in its demonstration of the non-inferiority
of s-ICDs relative to transvenous devices, notable differ-
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ences were present between arms, including inappropriate
shocks (driven by AF and supraventricular tachycardia in the
transvenous arm and cardiac over-sensing in the s-ICD arm)
and bleeding, albeit counterbalanced by infection. Limita-
tions of this study include a short follow-up duration with
respect to chronic complications and limited s-ICD longevity,
the use of a non-inferiority margin, and a high percentage of
patients lost to follow-up.
More recently, Gold et al. [28] evaluated the role of s-
ICDswith standardized device programming in 1111 primary
prevention patients with LVEF ≤35% in the Understand-
ing Outcomes With the S-ICD in Primary Prevention Pa-
tients With Low Ejection Fraction (UNTOUCHED) study.
Although a high level of freedom from inappropriate shocks,
shock-free, and complication free rates was reported, notable
limitations include a relatively short follow-up (18 months)
and a non-randomized study design. Complementary data
and longer term trends regarding the incidence of inappro-
priate shocks are due to be investigated in the EFFORTLESS
(NCT01085435) [29] and PAS trials (NCT01736618) [30],
while the ATLAS study will evaluate early andmid-term vas-
cular and lead-related complications (NCT02881255) [31].
3. Cardiac resynchronization therapy
3.1 Cardiac resynchronization therapy versus pharmacological
therapy
Cardiac resynchronization (CRT), or biventricular (BiV)
pacing, is a therapeutic option in HF patients with prolonged
QRS duration (≥150 ms) and LBBB morphology, and in pa-
tients with a QRS duration of 130–149 ms with LBBB de-
pending on NYHA classification [32]. The Comparison of
Medical Therapy, Pacing, and Defibrillation in Heart Failure
(COMPANION) study was the first randomized clinical trial
to evaluate the role of CRT or CRT-D versus optimal phar-
macological therapy in a cohort of 1520 patients with NYHA
class III/IV and QRS ≥120 ms (Table 2, Ref. [9, 10, 33–38])
[35]. At a median follow-up of 14.4 months, the primary
outcome of all-cause mortality or all-cause non-elective hos-
pitalization was significantly lower in the CRT arm. More-
over, the risk of death from any cause decreased by 24% with
CRT-pacemaker (CRT-P) and 36% with CRT-D. Although
earlier trials including the Multicenter InSync ICD Random-
izedClinical Evaluation (MIRACLE; CRTvs. no pacing) trial
[33] and MIRACLE-ICD (CRT with CRT capability turned
on vs. turned off) [34] demonstrated improvements in QoL
endpoints (e.g., 6-minute walk tests, NYHA functional class,
and functional capacity) these were not powered to address
the impact of CRT/ICD on mortality.
The survival benefits of CRT with or without defibrilla-
tor therapy were further supported by Cleland et al. [10] in
the Cardiac Resynchronization - Heart Failure (CARE-HF)
study. After randomization of 813 patients with NYHA class
III/IVHF andQRS>120ms to CRT versus optimal pharma-
cological therapy, a significantly lowered incidence of the pri-
mary endpoint (death from any cause or unplanned hospital-
ization for a major cardiovascular event) was reported in the
CRT group at a mean follow-up of 29.4 months. Moreover,
the authors reported a significant improvement in anatomical
ventricular remodelling and neurohormonal measures (e.g.,
N-terminal pro-brain natriuretic peptide), reflecting the re-
verse modelling impact of CRT.
3.2 Cardiac resynchronization therapy with CRT capability
turned on versus turned off
Although promising, the aforementioned findings were
later countered by data from Ruschitzka et al. [37] in the
Echocardiography Guided Cardiac Resynchronization Ther-
apy (ECHO-CRT) study, which randomized 809 NYHA class
III/IV HF patients to CRT with CRT capability turned on
versus turned off and showed a non-significant increase in a
predominantly cardiovascular death-driven all-cause mortal-
ity or first hospitalization forworseningHF. The participants
of this study were notably selected for narrow QRS≤130 ms
(mean cohort duration: 105ms; in contrast to COMPANION
andCARE-HF,median cohort duration: both 160ms), which
may indicate the presence of potentially adverse effects in re-
cipients of CRT with an exceptionally short QRS. Although
the benefits of CRT are greater in patients with severe QRS
(≥150 ms) versus moderately prolonged (120–149 ms) [39],
the effects of a mild-moderate QRS (e.g., 130–149ms) has yet
to be fully explored.
3.3 Cardiac resynchronization therapy versus implantable
cardioverter defibrillator
The role of CRT in combination with ICD in less severe
forms of HF have also been studied. In contrast to the CARE-
HF trial, Moss et al. [9] (Multicenter Automatic Defibrillator
ImplantationTrialwithCardiacResynchronizationTherapy,
MADIT-CRT study) randomized 1820 patients with LVEF
≤30%, QRS ≥130 ms, and NYHA class I/II HF to CRT plus
ICD versus ICD alone. The primary endpoint of all-cause
mortality or a non-fatal HF event was significantly reduced
in the CRT-ICD arm at a mean follow-up of 28.8 months,
driven predominantly by a 41% reduction in HF-related ad-
verse events. These benefits were more evident in NYHA
class II versus I recipients, highlighting the importance of risk
stratification.
The survival benefit of defibrillator therapy in patients
with mild-moderate NYHA class II/III HF, LVEF ≤30%,
and QRS ≥120 ms (intrinsic) or ≥200 (paced) was later
supported by Tang et al. [36] in the Resynchronization-
Defibrillation for Ambulatory Heart Failure Trial (RAFT).
After randomisation of 1798 patients to CRT/ICD or ICD
alone, the primary endpoint of all-cause mortality or hospi-
talization for HF occurred in 33.2% of CRT/ICD patients as
compared with 40.3% of ICD patients at a mean follow-up
of 40 months. However, as with MADIT-CRT, the 30-day
post-implant incidence of adverse events was significantly
higher in CRT/ICD, predominantly driven by lead dislodge-
ment requiring intervention, which may reflect an increased
complexity of the procedures performed.
418 Volume 22, Number 2, 2021
Table 1. Key randomized controlled trials of implantable devices in patients with HF, with a focus on survival outcomes and hospitalization for HF.
Study Year Number of participants (N) Follow-up (months) Intervention Death from any cause (HR; 95% CI) Hospitalization for HF (HR; 95% CI)
ICD
MADIT [12] 1996 196 27 ICD vs. medical therapy 0.46 (0.26–0.82); p = 0.009 N/A
MADIT II [13] 2002 1232 20 ICD vs. medical therapy 0.69 (0.51–0.93); p = 0.016
Defibrillator group: 148 (19.9%)
Medical therapy group: 73 (14.9%)
(number of patients hospitalised for HF)
DEFINITE [14] 2004 458 26 ICD plus medical therapy vs. medical therapy 0.65 (0.40–1.06); p = 0.08 N/A
SCD-HeFT [15] 2005 2521 45.5 ICD vs. amiodarone vs. placebo
Defibrillator: 0.77 (0.62–0.96); p = 0.007
N/A
Amiodarone: 1.06 (0.86–1.30); p = 0.53
DANISH [16] 2016 1116 68 ICD vs. medical therapy 0.87 (0.68–1.12); p = 0.28 N/A
s-ICD
PRAETORIAN [17] 2020 849 49.1 Subcutaneous vs. transvenous ICD 1.23 (0.89–1.70); p-value not provided 1.08(0.79–1.49)
Table 2. Key randomized controlled trials of CRT in patients with HF, with a focus on survival outcomes and hospitalization for HF.




Intervention Death from any cause (HR; 95% CI) Hospitalization for HF (HR; 95% CI)
MIRACLE [33] 2002 453 6 CRT vs. no-CRT 0.73 (0.34–1.54); p = 0.40 0.50 (0.28–0.88); p = 0.02
MIRACLE-ICD [34] 2003 369 6 CRT with CRT capability turned on vs. turned off
CRT on: 25.7% (95% CI, 19.6–32.3%) CRT on: 47.4% (95% CI, 40.0–54.4%)
CRT off: 25.9% (95% CI, 19.8–32.5%) CRT off: 48.3% (95% CI, 40.6–55.6%)
p = 0.69 p = 0.88
(probability of hospitalization for worsening
HF or death from any cause)
(probability of the risk of death or all–cause
hospitalization)
COMPANION [35] 2004 1520 14.4 CRT-P vs. CRT-D vs. medical therapy
CRT-P: 0.76 (0.58–1.01); p = 0.059 CRT-P: 0.66 (0.53–0.87); p = 0.002
CRT-D: 0.64 (0.48–0.86); p = 0.003 CRT-D: 0.60 (0.49–0.75); p < 0.001
(death from or hospitalization for HF)
CARE-HF [10] 2005 813 29.4 CRT-P vs. medical therapy 0.64 (0.48–0.85); p < 0.002 0.48 (0.36–0.64); p < 0.001
MADIT-CRT [9] 2009 1820 28.8 CRT-D vs. ICD
0.66 (0.52–0.84); p = 0.001 0.59 (0.47–0.74); p < 0.001
(risk of death or HF) (risk of HF)
RAFT [36] 2010 1798 40 CRT-D vs. ICD 0.75 (0.62–0.91); p = 0.003 0.68 (0.56–0.83); p < 0.001
ECHO-CRT [37] 2013 809 19.4 CRT with CRT capability turned on vs. turned off 1.81 (1.11–2.93); p = 0.02 1.16 (0.87–1.55); p = 0.25
BLOCK-HF [38] 2013 691 37 CRT-P or ICD with RV pacing vs. CRT-P or ICD
with biventricular pacing






3.4 Biventricular versus right ventricular pacing
More recently, the superior long-term clinical and func-
tional outcomes of BiV pacing in patients with high grade
atrioventricular block (AVB) and mild-to-moderate LV dys-
function has been shown. In the Biventricular versus Right
Ventricular Pacing in Heart Failure Patients with Atrioven-
tricular Block (BLOCK-HF) study, Curtis et al. [38] random-
ized 691 patients with NYHA class I-III, LVEF ≤50%, and
AVB to CRT-P or ICD with BiV versus right ventricular
(RV) pacing. At a mean follow-up of 37 months, the inci-
dence of death from any cause, urgent care visit for HF re-
quiring IV therapy, or an increase in LV end-systolic volume
index by ≥15% was significantly lower in the BiV group. In
addition, the benefits of BiV pacing were found to persist ir-
respective of NYHA class (therefore, it is suggested that CRT
may be the pacing modality of choice in patients with pre-
existing HF who are likely to require a high degree of pacing
support). Limitations include a high crossover rate, which
may reflect a greater benefit of CRT, and placement of an LV
lead in all patients, rendering it difficult to compare the rates
of complication between groups.
3.5 His-bundle pacing
His-bundle conduction pacing (HBP) has more recently
emerged as a viable alternative to BiV and RV pacing, achiev-
ing a physiological pattern of ventricular activation via the
native His-Purkinje system. In particular, the use of HBP in
conjunction with an LV lead (i.e., His-optimized CRT) has
been shown to shorten LV activation times by ≥10 ms [40]
as well as to reduce baseline QRS and to increase LVEF [11],
reflecting an improvement in electrical synchrony. More re-
cently, Sohaib et al. [2] showed AV-optimized HBP in 16
consecutive patients with HF and PR prolongation with ei-
ther a normal QRS or right bundle branch block (RBBB)
to improve acute haemodynamic function. Future comple-
mentary findings will be provided by the HOPE-HF study
(NCT02671903) which aims to evaluate the role of AV de-
lay optimisation via HBP on changes in exercise capacity in
patients with PR interval ≥200 ms, LVEF <40%, and either
narrow QRS (≤140 ms) or RBBB, and the His-SYNC study
(NCT02700425) whichwill investigate the safety and efficacy
of HBP versus CRT.
Although promising, various clinical concerns are associ-
atedwithHBP including a longer andmore demanding learn-
ing curve [41], failed corrections of bundle branch block [42],
and high HBP capture thresholds at implant and/or during
late follow-up leading to premature battery depletion [43].
To address this, left bundle branch area pacing (LBBAP) has
emerged as a safe and feasible technique for the delivery of
physiological pacing in the event of failed HBP (demonstrat-
ing higher rates of implant success and lower lead-related
complications [44, 45]), and as a valuable alternative to con-
ventional CRT (demonstrating significant QRS narrowing
and improvements in LVEF [46, 47]). However, future large
prospective and randomized studies are needed to further
verify the long-term safety and effectiveness of this pacing
modality.
4. Left ventricular assist devices
Mechanical circulatory support via left ventricular assist
device (LVAD) therapy is typically used in patients with
drug-refractory end-stage HF as either a bridge to cardiac
transplantation, bridge to recovery, or as destination ther-
apy in terminal cardiac dysfunction. The landmark Random-
ized Evaluation of Mechanical Assistance for the Treatment
of Congestive Heart Failure (REMATCH) study by Rose et
al. [48] randomized 129 patientswith symptomatic end-stage
HF and an ineligibility for cardiac transplantation to LVAD
therapy versus optimal medical therapy. Although all-cause
mortality was significantly lower in the LVAD group, this
study reported significant morbidity and prolonged hospital-
ization alongside a 1-year survival rate of 52% in the LVAD
group and 25% in the medical therapy group, and 2-year sur-
vival rate of 23% and 8%, respectively. In addition, the fre-
quency of serious adverse events for LVAD was 2.35 times
that of the medical therapy group, with a predominance of
infection (28% at 3 months), bleeding (42% at 6 months),
and risk of device malfunction (35% at 2 years) albeit coun-
tered by significant improvements in QoL as determined by
SF-36 score, Beck depression inventory, and median NYHA
class. Nevertheless, this study was the first to demonstrate
a clinically meaningful survival benefit after LVAD therapy
in patients with advanced HF, and its viability as a therapeu-
tic option in select patients who are not candidates for car-
diac transplantation. Recent meta-analyses have additionally
supported the survival benefits of LVADs in comparison to
medical management, with newer generations (e.g., Heart-
Mate 3 and HeartWare) faring better than older generations
(e.g., HeartMate II andHeartMateXVE/VE) for bleeding, de-
vice thrombosis, and stroke risk, albeit associated with worse
adverse events e.g., drive-line exit-site infection [49]. Given
the prevalence of comorbid conditions in HF, neither dia-
betes mellitus (DM) [50], pre-operative AF [51] nor prior
CRT [52] have been shown via meta-analysis to significantly
influence all-cause mortality post-LVAD.
5. Catheter ablation for atrial fibrillation
5.1 Catheter ablation versus rate control therapy
A number of clinical trials have demonstrated catheter ab-
lation for AF in patients with HF to be safe and superior to
pharmacological therapy, particularly if refractory or intol-
erant to medication [53]. The superiority of catheter abla-
tion over rate control has been established in various small-
scale trials and early randomized controlled trials (e.g., ARC-
HF, CAMTAF, CAMERA-MRI). These studies showed an
association between catheter ablation and significant im-
provements in LVEF, QoL (via Minnestoa living with HF
questionnaire score), cardiopulmonary exercise performance
(measured by peak oxygen consumption), B-type natriuretic
peptide levels, and freedom from AF at follow-up (Table 3,
Ref. [54–69]) [55–57, 59, 70].
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Table 3. Key randomized controlled trials of catheter ablation for AF and VT in patients with HF.
Atrial fibrillation
Study Year Number of participants (N) Follow-up (months) Intervention Improvement in LVEF Freedom from AF
PABA-CHF [54] 2008 81 6
CA vs. AV nodal ablation plus
biventricular pacing
+8% vs. –1%
Patients receiving AADs: 88%
Patients not receiving AADs: 71%
MacDonald et al. [55] 2011 41 12 CA vs. rate control +4.5% vs. +2.8%
CA: 50%
Rate control: 0%
ARC-HF [56] 2013 52 12 CA vs. rate control +10.9% vs. +5.4
CA: 88%
Rate control: rate criteria was achieved in 96% patients
CAMTAF [57] 2014 50 12 CA vs. rate control +8.1% vs. −3.6%
CA: 73%
Rate control: 0%
AATAC [58] 2016 203 24 CA vs. amiodarone +8.1% vs +6.2%
CA: 70%
Amiodarone: 34%
CAMERA-MRI [59] 2017 66 6 CA vs. rate control +18% vs. 4.4%
CA: 100%
Rate control: 0%
CASTLE-AF [60] 2018 363 60 CA vs. rate or rhythm control +8.0% vs. +0.2%
CA: 63.1%
Rate or rhythm control: 21.7%
AMICA [61] 2019 140 12 CA vs. rate or rhythm control +8.8% vs. +7.3%
CA: 73.5%
Rate or rhythm control: 50%
CABANA-AF [62] 2019 2204 60 CA vs. rate or rhythm control N/A
CA: 84%
Rate or rhythm control: 74%
CIRCA-DOSE [63] 2019 346 12
Contact force–guided radiofrequency
ablation vs. 4-minute cryoballoon ablation
vs. 2-minute cryoballoon ablation
N/A
53.9% vs. 52.2% vs. 51.7%
(Freedom from any atrial tachyarrhythmia, after a single ablation
procedure, with 90-day blanking period)
Ventricular tachycardia
Study Year Number of participants (N) Follow-up (months) Intervention Survival Freedom from VT
SMASH-VT [64] 2007 128 22.5 CA plus ICD vs. ICD 99% vs. 83%
CA plus ICD: 88%
ICD: 67%
VTACH [65] 2010 110 24 CA plus ICD vs. ICD 90.4% vs. 92.7%
CA plus ICD: 47%
ICD: 29%
HELP-VT [66] 2014 227 12





VANISH [67] 2016 259 27.9 CA vs. rhythm control 72.7% vs. 72.7%
CA: 57.6%
Rhythm control: 57.5%
(Freedom from appropriate ICD shock at any time)
SMS [68] 2017 111 27.6 CA plus ICD vs. ICD 90.2% vs. 80.7%
CA plus ICD: 49%
ICD: 52%
BERLIN-VT [69] 2020 163 12





(Freedom from sustained VT)
ARC-HF, A Randomized Trial to Assess Catheter Ablation Versus Rate Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure; CA, catheter ablation; CAMERA-MRI,
Catheter Ablation versusMEdical Rate control in Atrial fibrillation and heart failure – AnMRI guided multi-centre randomized controlled trial; CAMTAF, Catheter Ablation VersusMedical Treatment






5.2 Catheter ablation versus antiarrhythmic drug therapy
The Ablation versus Amiodarone for Treatment of Atrial
Fibrillation in Patients With Congestive Heart Failure and
an Implanted ICD/CRT-D (AATAC) study by Di Biase et al.
[58] was the first randomized trial to compare the efficacy
of catheter ablation versus amiodarone. After randomiza-
tion of 203 patients with persistent AF, NYHA II/III, LVEF
≤40%, and an implanted dual chamber ICD/CRT-D, a 45%
relative risk reduction in unplanned hospitalizations and a
56% relative risk reduction in mortality was reported in the
catheter ablation group at 2-year follow-up. Although lim-
ited in design (i.e., providing a comparison against an AAD
with significant known toxicities) these findings importantly
highlighted the superiority of catheter ablation over AADs in
achieving and maintaining sinus rhythm.
The Catheter Ablation versus Standard Conventional
Therapy in Patients with Left Ventricular Dysfunction and
Atrial Fibrillation (CASTLE-AF) study by Marrouche et al.
[60] was later conducted to assess cardiovascular outcomes in
catheter ablation versus standard treatment. After random-
ization of 363 patients with symptomatic paroxysmal or per-
sistent AF, NYHA II-IV, LVEF≤35%, and a prior implanted
ICD/CRT-D, catheter ablation was associated with a signifi-
cant 16.1% absolute reduction in death or hospitalization for
HF, with a greater proportion of patients in sinus rhythm
versus standard treatment (63.1% versus 21.7%, respectively),
at 5-years follow-up. Whether these findings are equally ap-
plicable in ischaemic and non-ischaemic aetiologies, aswell as
asymptomatic AF, remains unclear. Nevertheless, this study
was able to provide the first critical step toward the sugges-
tion that catheter ablation may represent a reasonable first-
line treatment in patients with HF.
In another prospective trial, Kuck et al. [61], the
Atrial Fibrillation Management in Congestive Heart Failure
With Ablation (AMICA) study investigated the influence of
catheter ablation versus best medical therapy on the primary
outcome of LVEF in addition to 6-minute walk test, QoL,
and NT-proBNP, in a persistent or longstanding persistent
AF and LVEF≤35% patient cohort. Prematurely terminated
due to futility, this study did not report a significant differ-
ence in LVEF nor in the restoration of sinus rhythm at 1-year
follow-up. This observation may be partly explained by the
enrolment of a patient population with lower baseline LVEF
and NYHA as well as a short duration of follow-up. Notably,
the 1-year increase in LVEF following catheter ablation was
similar between AMICA, CASTLE-AF, and AATAC trials.
The influence of catheter ablation in patients with new-
onset or untreated AF was more recently investigated by
Packer at al. in the Catheter Ablation versus Antiarrhythmic
Drug Therapy for Atrial Fibrillation (CABANA-AF) study
[62]. Although randomization of 2204 patients to either
catheter ablation or medical therapy failed to demonstrate
the superiority of catheter ablation with respect to the pri-
mary endpoint of death, disabling stroke, serious bleeding,
or cardiac arrest at 5-year follow-up, patients randomized to
catheter ablation did, however, demonstrate a significant re-
duction in AF recurrence as well as the rate of death or car-
diovascular hospitalization. Although promising, it is impor-
tant to highlight the heterogeneous nature of the drug ther-
apy arm that was used in addition to the single-blinded study
design. The latter may explain the high crossover rate, which
may have led to an underestimation of ablation benefit.
Recent advances in the delivery of catheter ablation for AF
have emerged in the form of contact-force-guided radiofre-
quency ablation and second-generation cryoballoon ablation.
To explore these technologies, the Cryoballoon versus Irri-
gated Radiofrequency Catheter Ablation: Double Short vs
Standard Exposure Duration (CIRCA-DOSE) study by An-
drade et al. [63] was established to evaluate the efficacy and
safety profile of newer contact force-guided radiofrequency
(RF) ablation technologies. This was performed in 346 pa-
tients with symptomatic paroxysmal AF refractory to Class
I/II AADs and referred for a first catheter ablation procedure,
randomized to contact-force irrigated RF ablation, cryobal-
loon ablation using 2-minute cryoapplications (CRYO-2), or
cryoballoon ablation using standard 4-minute cryoapplica-
tions (CRYO-4). At 12-months follow-up, no significant
difference in freedom from recurrent atrial tachyarrhythmia
on continuous rhythm monitoring, symptomatic AF or AF
burden, nor in the frequency of complications was reported.
In addition to demonstrating equal effectiveness, this study
showed that a 4-minute freezing duration is not necessarily
required in place of a shorter 2-minute cryoapplication.
Complementary data on this topic will be provided by
the RAFT-AF study (NCT01420393) which will investigate
whether catheter ablation, with or without AAD therapy, re-
duces all-cause mortality and hospitalization for HF versus
rate control in patients with a high burden of AF and NYHA
class II/III.
6. Catheter ablation for ventricular
tachycardia
6.1 Catheter ablation and ICD therapy
ICD therapies are used to terminateVT by antitachycardia
pacing (ATP) or the delivery of a direct current shock, how-
ever they cannot prevent the recurrence of VT. Since ICD
shocks are associated with increased morbidity and mortal-
ity, owing to physiological distress and physical trauma, the
main treatment options to reduce the frequency and recur-
rence of VT include AADs or catheter ablation [71].
The Substrate Mapping and Ablation in Sinus Rhythm to
Halt Ventricular Tachycardia (SMASH-VT) study by Reddy
et al. [64] was established to evaluate whether prophylactic
VT ablationwithin 6months after secondary prevention ICD
implantation, in patients with spontaneousVT/VF and a his-
tory of myocardial infarction, would reduce the incidence of
ICD therapy (Table 3). After randomization of 128 patients
to defibrillatorwith adjunctive catheter ablation versus defib-
rillator implantation alone, the primary endpoint of survival
free from any appropriate ICD therapy, in addition to free-
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dom from ICD shocks, was significantly greater in catheter
ablation patients at a mean follow-up of 22.5 months. Al-
though overall mortality was lower with catheter ablation,
this did not reach statistical significance.
A strategy of prophylactic catheter ablation for VT plus
ICD versus ICD alone was later evaluated by Kuck et al. [65]
in the Ventricular Tachycardia Ablation in Coronary Heart
Disease (VTACH) study. After randomization of 110 patients
with haemodynamically tolerated VT, prior myocardial in-
farction, and a LVEF≤50%, the primary outcome of median
time to first VT or VF episode was significantly greater in the
prophylactic ablation group at 2-year follow-up. Moreover,
the event-free survival rate was statistically significant be-
tween groups as was the mean number of appropriate shocks
per patient per year (0.6 vs. 3.4, respectively). Althoughmor-
tality was similar between groups, as with SMASH-VT, this
study added to an increasing body of evidence to support the
prophylactic use of VT ablation among patients with an un-
derlying ischaemic pathology.
In contrast to SMASH-VT and VTACH, the Substrate
Modification Study (SMS) was more recently conducted to
determine whether prophylactic catheter ablation of the ar-
rhythmogenic substrate in 111 patients with unstable VT,
LVEF ≤40%, and coronary artery disease reduces or pre-
vents the recurrence of VT/VF [68]. Although a similar 2-
year event-free survival was observed between groups at 27.6
months follow-up, the number of spontaneous ventricular
arrhythmia episodes was significantly reduced in the abla-
tion group (2.8 vs. 8.1, respectively) including the number of
episodes requiring ATP or shock (2.8 vs. 12.9, respectively).
The role of preventive versus deferredVT ablation among
patients undergoing an ICD implant has since been investi-
gated in the Preventive Ablation of Ventricular Tachycardia
in PatientsWithMyocardial Infarction (BERLIN-VT) study,
which randomized 163 patients with a history of prior MI
with stable ischaemic CM and LVEF 30–50% [69]. Termi-
nated due to futility, the primary outcome of a composite
of all-cause death and unplanned hospitalization for either
symptomatic ventricular arrhythmia or worsening HF was
significantly higher in the preventative group. However, sev-
eral secondary endpoints were in favour of prevention in-
cluding the incidence of sustained ventricular arrhythmias
and the incidence of ICD therapies. Together with SMASH-
VT and VTACH, these studies were able to provide evi-
dence to support the use of preventative VT ablation in post-
infarction patients.
Whether the long-term arrhythmia-free survival benefits
of catheter ablation for VT would extend to a non-ischaemic
cardiomyopathy patient cohort was investigated by Dinov
et al. [66] in the Heart Center of Leipzig VT (HELP-VT)
trial. Although the difference in VT-free survival at 1-year
follow-up in non-ischaemic versus ischaemic cardiomyopa-
thy did not reach statistical significance, there were various
limitations to this study, including a non-randomized de-
sign and the reporting of outcomes after a single VT abla-
tion procedure. As a whole, it is recommended that a more
comprehensive approach to VT management, including re-
peat VT ablation, epicardial mapping, and aims for complete
VTnon-inducibility, are used in patients with non-ischaemic
cardiomyopathy.
6.2 Catheter ablation versus rate or antiarrhythmic drug therapy
With the exception of beta-blockers, existing pharmaco-
logical therapy has not been shown to be effective in theman-
agement of patients with ventricular tachyarrhythmia [72].
In theVentricular Tachycardia Ablation versus EscalatedAn-
tiarrhythmicDrugTherapy in IschemicHeartDisease (VAN-
ISH) study, Sapp et al. [67] performed the first randomized
trial to compare VT ablation with escalation of AAD ther-
apy in 259 patients with ischaemic cardiomyopathy, ICD, and
persistent VT despite AADs (predominantly amiodarone).
At a mean follow-up of 27.9 months, the primary outcome
of a composite of death, VT storm, or appropriate ICD shock
after 30-days of treatment occurred in 59.1% of patients in
the ablation group and 68.5% of patients in the escalatedAAD
group. In the ablation group, this finding was predominantly
driven by a reduction in the rates of appropriate ICD stocks
and VT storm. The superiority of VT ablation was, how-
ever, not associated with a significant difference in mortality.
Although high impact in its demonstration of the ability of
ablation to be more effective at reducing recurrent VT than
escalation of AAD, this trial suffered from a number of im-
portant limitations, including the use of an open-label design
and inadequate power for detecting differences in mortality.
In a more recent retrospective analysis of the 2002–2014
Nationwide Inpatient Sample, the efficacy and safety profile
of VT ablation in HFrEF versus medical therapy was shown
to significantly lower in-hospital mortality, in contrast to
VANISH, albeit with high rates of post-operative haemor-
rhage, myocardial infarction, and pericardial and neurologi-
cal complication [73]. Although future prospective trials are
needed to fully investigate and verify these outcomes, factors
that have been postulated to act as barriers to the recruitment
of patients and the completion of long-term endpoints in tri-
als of VT ablation include funding challenges, patient referral
as a ‘last resort’, and factors that may dissuade patients from
continuing enrolment (e.g., randomization to a non-ablation
arm).
7. Discussion
HF is a highly debilitating condition and major pub-
lic health concern associated with significant morbidity and
mortality worldwide. Several large-scale clinical trials have
since established the role of implantable devices in the man-
agement of HF, which has evolved significantly over the
past few decades. LVAD systems have undergone substan-
tial progress in durability and reliability as destination ther-
apy for end-stage HF, while ICDs continue to be used in the
primary prevention of SCD. Although s-ICDs were designed
to address the limitations of transvenous ICD systems, these
patients must be carefully selected due to a propensity for
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t-wave oversensing, an inability to provide antitachycardia
pacing nor CRT, and limited capacity for continuous brady-
cardia pacing [74, 75]. Contraindications to s-ICD use there-
fore includes a previously implanted unipolar pacemaker, VT
that is known or anticipated to be responsive to antitachy-
cardia pacing, HF and LBBB indicated for CRT, and symp-
tomatic bradycardia requiring permanent pacing [74]. In
general, s-ICDs are considered in younger patients, those
with congenital cardiomyopathies or genetic arrhythmia syn-
dromes, candidates for ICDwithout concurrent need for pac-
ing, patients at high risk of bacteraemia (e.g., dialysis), or in
the event of challenging vascular access [74].
In addition to ICDs, CRT systems have continued to
demonstrate meaningful improvements in clinical outcome
with respect to mortality and hospitalization for HF. How-
ever, there continues to exist a group of patients for whom
the indication for CRT is controversial (i.e., RBBB), and ap-
proximately one third of patients with an indication for CRT
have a suboptimal clinical response (i.e., “non-responders”)
[76]. Causes of non-response include mechanical dyssyn-
chrony, presence and extent of myocardial scar, and subopti-
mal LV lead position [77–79]. Other factors that have been
shown to influence response to CRT include QRS width and
morphology pattern, device optimization, and post-implant
programming [80, 81]. With respect to future directions,
alternative modes of LV pacing with the capacity to over-
come the limitations of non-response include isolated LV
pacing (potential as a tiered therapy) [82], endocardial pac-
ing (LV end-systolic volume reduction in patients enrolled
after CRT non-response) [83], septal pacing (short-term
haemodynamic improvements and electrical resynchroniza-
tion on par with BiV pacing) [84], and multipoint LV pac-
ing (reductions in hospitalization for HF, improved LVEF
on follow-up, and an increase in CRT response) [85]. Risk
stratification has also become increasingly important to help
identify those patients most likely to benefit. Selection is
supported by circulating biomarker red cell width distribu-
tion and platelet count levels (which independently predict
long-term all-cause mortality and reverse LV remodelling in
CRT) [86], ScREEN scoring (Sex category, Renal function,
ECG/QRS width, Ejection fraction and NYHA class) [87],
contractile reserve [88] and the Charlson Age-Co-morbidity
Index (CACI) [89]. In addition to non-response, a therapeu-
tic gap continues to exist in the treatment of patients that are
ineligible for CRT. Ultimately, restoring conduction to near-
normal physiology is the predominant aim, and in those with
suitable anatomy, conduction system pacing has been shown
to be a viable alternative or potential first-line approach.
Catheter ablation is superior to pharmacological therapy
in providing rhythm control in patients with symptomatic
AF and in improving functional status, QoL, LVEF, fre-
quency of hospitalization for HF, and mortality parameters
in patients. These underlying pathophysiological benefits
stem from the successful restoration of sinus rhythm, em-
phasizing the importance of timely intervention. Radiofre-
quency (RF)-based circumferential pulmonary vein isolation
(PVI) remains the cornerstone approach irrespective of AF
type, and mounting epidemiological evidence and random-
ized data have increasingly highlighted the importance of risk
factor management in improving successful post-procedural
outcomes (e.g., obesity and sedentary lifestyle) [90]. Impor-
tantly, this should involve risk stratification and optimal pa-
tient selection based on individualized clinical assessment and
physiological characteristics, together with the risks of abla-
tive technology.
Although multiple-procedure success rates of PVI in pa-
tients with AF range 50–80%, efficacy remains suboptimal
in patients with persistent and long-standing persistent AF
[91]. The success of ablation therefore depends on various
physiological factors, including the type and duration of AF
(e.g., paroxysmal versus persistent), structural heart remod-
elling, atrial wavelets and multiple macro re-entry circuits
that complicate procedural success, in addition to insufficient
lesion formation during the index procedure [92]. Inno-
vative tools that have more recently emerged to overcome
the limitations of existing ablative technology include single-
shot pulmonary vein isolation modalities in the form of cry-
oballoon (e.g., CRYO4PERSISTENTAF trial, demonstrating
a 61% single-procedure success at 12 months post-ablation)
[93, 94], cardiacmagnetic resonance imaging-guided LA sub-
strate modification in addition to standard PVI using cryoab-
lation [95], laserballoon ablation (demonstrating similar ef-
ficacy as wide-area circumferential PVI using irrigated RF
in persistent AF) [96], in addition to the use of markers of
ablation lesion quality (e.g., ablation index) [97] and contact
force-sensing technologies [98]. Irreversible electroporation
may overcome the complications of thermal ablation includ-
ing pulmonary vein stenosis and oesophageal ulceration via
the generation of a high electrical field, however this has yet
to be investigated clinically [99]. In patients with VT, chal-
lenges including the identification of optimal timing for VT
ablation and the most suitable indications with respect to pa-
tient parameters remain.
Additional advances in the field of implantable devices and
catheter ablation are likely to involve further incremental im-
provements to design and integrated telemetric programma-
bility. The future of HF management may also see the rise of
novel technologies complexed with biologically active com-
ponents to reverse myocardial dysfunction.
8. Conclusions
Implantable device therapy and catheter ablation have
progressed significantly over the past few decades. However,
there continues to remain numerous areas of active investiga-
tion aimed at reducing the incidence of patients with HF that
do not respond to CRT and to minimizing the recurrence of
arrhythmia post-ablation. Although numerous management
strategies have emerged to address this, future large scale and
randomized trials are needed to confirm their feasibility of
implementation, long-term safety, and effectiveness in clini-
cal practice.
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